Company Performance - Alexander's (ALX) has gained approximately 6.2% year-to-date, outperforming the average gain of 1% in the Finance sector [4] - The Zacks Consensus Estimate for ALX's full-year earnings has increased by 15% over the past quarter, indicating a positive earnings outlook [3] Industry Context - Alexander's is part of the REIT and Equity Trust - Other industry, which consists of 98 companies and is currently ranked 131 in the Zacks Industry Rank [5] - The average gain for the REIT and Equity Trust - Other industry is 3.3% year-to-date, showing that Alexander's is performing better than its industry peers [5] - Banco Bilbao (BBVA), another stock in the Finance sector, has significantly outperformed with a year-to-date increase of 47.5% [4]

Core Insights - ALX Oncology presented positive data from the ASPEN-06 Phase 2 trial, showing that evorpacept provides strong responses and durable clinical benefits in HER2-positive gastric cancer patients [1] - The company announced a focused development plan for evorpacept, including clinical trials in breast and colorectal cancers, and a new EGFR-targeted antibody-drug conjugate [1][4] - ALX Oncology's strategic prioritization and resource optimization efforts are expected to extend its cash runway into Q4 2026 [1][4] Clinical Developments - Updated results from the ASPEN-06 trial indicated a confirmed objective response rate (cORR) of 48.9% and a median duration of response (mDOR) of 15.7 months for evorpacept compared to 24.5% cORR and 9.1 months mDOR in the control group [4] - At the SABCS 2024, evorpacept in combination with zanidatamab showed a cORR of 55.6% and a median progression-free survival (mPFS) of 7.4 months in HER2-positive metastatic breast cancer patients [4] Financial Performance - As of December 31, 2024, ALX Oncology reported cash, cash equivalents, and investments totaling $131.3 million, sufficient to fund operations into Q4 2026 [6][12] - R&D expenses for Q4 2024 were $23.5 million, a decrease from $41.8 million in the prior year, primarily due to reduced clinical and development costs [6][11] - The GAAP net loss for Q4 2024 was $29.2 million, down from $45.5 million in Q4 2023, attributed to lower R&D expenses [8][11] Leadership Changes - ALX Oncology announced key additions to its leadership team, including Dr. Allison Dillon as Chief Business Officer and Dr. Alan Sandler as Chief Medical Officer [2][7] - The company is streamlining its organization, resulting in approximately a 30% workforce reduction primarily in preclinical research [4]

Alexander's (ALX) Q4 2024 Earnings Call February 11, 2025 10:32 PM ET Company Participants Steven Borenstein - EVP & Corporation CounselSteven Roth - Chairman & Chief Executive OfficerMichael Franco - President & CFOGlen Weiss - Executive VP of Office Leasing & Co-Head of Real EstateJohn Kim - Managing Director - US Real EstateJeffrey Spector - Managing DirectorVikram Malhotra - Managing DirectorMichael Lewis - Cyber Security Group ManagerAlexander Goldfarb - Managing DirectorRonald Kamdem - Managing Direct ...

Group 1 - Alexander's reported quarterly funds from operations (FFO) of $4.06 per share, exceeding the Zacks Consensus Estimate of $3.71 per share, but down from $4.99 per share a year ago, representing an FFO surprise of 9.43% [1] - The company posted revenues of $55.91 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.29%, but down from $62.94 million year-over-year [2] - Over the last four quarters, Alexander's has surpassed consensus FFO estimates three times and topped consensus revenue estimates three times [2] Group 2 - The stock has underperformed the market, losing about 1% since the beginning of the year compared to the S&P 500's gain of 2.5% [3] - The current consensus FFO estimate for the coming quarter is $3.29 on revenues of $55.5 million, and for the current fiscal year, it is $10 on revenues of $223.5 million [7] - The Zacks Industry Rank for REIT and Equity Trust - Other is currently in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

PARAMUS, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- ALEXANDER’S, INC. (New York Stock Exchange: ALX) filed its Form 10-K for the year ended December 31, 2024 today and reported: Fourth Quarter 2024 Financial Results Net income for the quarter ended December 31, 2024 was $12.3 million, or $2.39 per diluted share, compared to $16.3 million, or $3.17 per diluted share for the quarter ended December 31, 2023. Funds from operations (“FFO”) (non-GAAP) for the quarter ended December 31, 2024 was $20.8 million, or $4. ...

Revenue and Income - Bloomberg accounted for rental revenues of $125.35 million, $120.35 million, and $115.13 million for the years ended December 31, 2024, 2023, and 2022, respectively, representing approximately 55%, 54%, and 56% of total rental revenues[23]. - 731 Lexington Avenue generated revenues of $153.3 million, $148.8 million, and $138.8 million for the years ended December 31, 2024, 2023, and 2022, respectively, accounting for approximately 68%, 66%, and 67% of total rental revenues[44]. - Rental revenues increased to $226,374,000 in 2024 from $224,962,000 in 2023, an increase of $1,412,000, primarily due to higher rental revenue from Bloomberg's lease extension[152]. - Net income for the year ended December 31, 2024, was $43,444,000 or $8.46 per diluted share, a decrease from $102,413,000 or $19.97 per diluted share in 2023[142]. - Funds from operations (FFO) for the year ended December 31, 2024, was $77,968,000 or $15.19 per diluted share, compared to $81,067,000 or $15.80 per diluted share in 2023[143]. - Comprehensive income for 2024 was $31,130,000, down from $93,028,000 in 2023, a decrease of 66.6%[211]. Property and Development - The Rego Park I shopping center will be vacant in 2025 after the relocation of Burlington and Marshalls, and the company is exploring sale and development opportunities for the property[22]. - The company is exploring sale and development opportunities for the vacant Rego Park I property[119]. - As of December 31, 2024, the portfolio comprised five properties totaling 2,455,000 square feet, with a commercial occupancy rate of 99.1% and a residential occupancy rate of 94.2%[144]. Financial Position and Debt - As of December 31, 2024, total mortgages payable amounted to $996,544,000, with a total debt to total enterprise value ratio of 59%[67]. - The company faces risks associated with its outstanding debt, including potential difficulties in refinancing on acceptable terms, which could adversely affect future operations[67]. - Total liabilities were $1,164,436,000 as of December 31, 2024, compared to $1,166,023,000 in 2023[205]. - The company anticipates that cash flow from continuing operations will be adequate to fund business operations, cash dividends, debt service, and capital expenditures over the next twelve months[163]. Operational Risks - The company faces risks from trends in office real estate, including the prevalence of work-from-home policies, which could affect tenant space utilization and rental revenues[36]. - The company is subject to various risks affecting the retail environment, including consumer spending levels, tourism, and competition from online retailers[39]. - The company faces risks related to tenant bankruptcies, which could lead to decreased revenues and operational difficulties, impacting cash flow and distributions to stockholders[47]. - Significant inflation could adversely affect the company's ability to raise rental rates, potentially reducing profit margins and increasing operating costs[61]. - The company is exposed to risks associated with property development and redevelopment, including cost overruns and regulatory approval delays, which could adversely affect financial results[63]. Insurance and Compliance - The company maintains general liability insurance with limits of $300 million per occurrence and property insurance coverage of $1.7 billion per occurrence, including terrorism coverage[49]. - The company is subject to various federal, state, and local regulatory requirements, and noncompliance could result in substantial costs[99]. - The company may incur significant costs due to potential adverse federal tax audits and changes in federal tax laws[95]. Environmental and Sustainability Initiatives - Vornado has adopted a 10-year plan, "Vision 2030," to make its buildings carbon neutral by 2030, focusing on energy reduction, recovery, and renewable power[25]. - Vornado operates over 26 million square feet of LEED certified buildings, representing 100% of its certifiable office portfolio, with over 24 million square feet at LEED Gold or Platinum[25]. - The company is subject to transitional risks related to climate-related policy changes, which could lead to increased operating costs and compliance expenses[57]. - The impact of climate change and natural disasters could significantly damage properties and affect demand, leading to adverse financial results[55]. Cybersecurity - The company has implemented various measures to manage cybersecurity risks, but there is no assurance that these measures will be fully effective against evolving threats[87]. - A significant disruption in IT networks could adversely affect operations and result in unauthorized access to sensitive information, potentially harming financial results[88]. - The company has a comprehensive cybersecurity risk management strategy integrated into its overall enterprise risk management program[105]. - The Board of Directors oversees cybersecurity risks, with the Audit Committee responsible for the implementation of the cybersecurity risk management program[107]. Shareholder and Stockholder Matters - Vornado and its affiliates collectively own approximately 58.4% of the outstanding shares of common stock, potentially reducing the likelihood of a tender offer or change in control[77]. - The company may change its operational and financial policies without stockholder approval, limiting stockholder control over significant decisions[78]. - As of December 31, 2024, the company had authorized but unissued 4,826,550 shares of common stock and 3,000,000 shares of preferred stock, which could dilute current stockholders' interests[92]. - The company is dependent on key personnel, including Steven Roth, the Chairman and CEO, and their loss could adversely affect operations and stock value[93].

Core Points - Alexander's, Inc. has declared a quarterly dividend of $4.50 per share, payable on February 28, 2025, to stockholders of record on February 18, 2025 [1] - The company operates as a real estate investment trust (REIT) with five properties located in New York City [1] Company Summary - The Board of Directors of Alexander's, Inc. has made a decision to distribute dividends, indicating a commitment to returning value to shareholders [1] - The dividend announcement reflects the company's financial health and operational stability within the real estate sector [1]

Stock Performance - Alexander's (NYSE: ALX) stock price has declined by 24% from its 52-week high, reflecting a broader selloff in the REIT market over the past four months since October [1] Dividend Information - ALX last declared a quarterly cash dividend, though the specific amount is not mentioned in the article [1] Market Mechanism - The equity market is described as a powerful mechanism where daily price fluctuations aggregate to significant long-term wealth creation or destruction [1] Investment Strategy - Pacifica Yield focuses on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend tickers, REITs, and green energy firms [1]

Core Message - ALX Oncology announced positive updated data from the ASPEN-06 Phase 2 clinical trial for evorpacept, a CD47-blocker, showing durable clinical response and a well-tolerated safety profile in HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer patients [1] - The updated results were presented at the 2025 ASCO Gastrointestinal Cancers Symposium, highlighting evorpacept as the first CD47 blocker to show substantial tumor response in a prospective randomized trial [5] Clinical Trial Results - The ASPEN-06 trial demonstrated an overall response rate (ORR) of 41.3% in the intent-to-treat (ITT) population for evorpacept plus TRP (ETRP), compared to 30% for RP historical control and 26.6% for TRP control [6] - In patients with fresh HER2-positive biopsies, ETRP showed an ORR of 59.1%, compared to 30% for RP historical control and 23.1% for TRP control [6] - Median duration of response (mDOR) was 15.7 months for ETRP in the ITT population, compared to 9.1 months for TRP control [6] - Median progression-free survival (mPFS) was 7.5 months for ETRP in the ITT population, compared to 7.4 months for TRP control [6] - In patients with confirmed HER2-positive expression, ETRP resulted in a 48.9% ORR, mDOR of 15.7 months, and mPFS of 7.5 months, compared to 24.5% ORR, mDOR of 9.1 months, and mPFS of 6.7 months in the TRP control group [7] Safety Profile - Evorpacept plus TRP was generally well tolerated, with adverse events consistent with those in the TRP control group [7] Regulatory Status - The FDA has granted Fast Track designation to evorpacept for the second-line treatment of HER2-positive gastric or GEJ carcinoma [9] - Both the FDA and European Commission have granted Orphan Drug Designation for this indication [9] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that boost the immune system to treat cancer [11] - Evorpacept, the company's lead therapeutic candidate, is being evaluated in multiple ongoing clinical trials across various cancer indications [11] Presentation and Webcast - The updated ASPEN-06 data were presented at the 2025 ASCO Gastrointestinal Cancers Symposium [5] - ALX Oncology hosted a conference call and webcast on January 23, 2025, to review the updated data [10]

Company Announcement - ALX Oncology granted an inducement stock option to purchase 600,000 shares of common stock to Harish Shantharam, the Chief Financial Officer, effective January 21, 2025 [1] - The stock option has an exercise price of $1.65 per share, equal to the closing price on the grant date [2] - The option vests as follows: 25% on the one-year anniversary of January 21, 2025, and an additional 1/48th monthly thereafter, contingent on continued employment [2] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing therapies that enhance the immune system to treat cancer and extend patient lives [3] - The company's lead therapeutic candidate, evorpacept, is being evaluated in multiple ongoing clinical trials across various cancer indications [3] - Evorpacept has shown potential to serve as a cornerstone therapy in immuno-oncology [3]